News

Published on 16 Oct 2024 on Insider Monkey · via Yahoo Finance

Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According...


Article preview image

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other promising biotech stocks.

Biotechnology stocks are known for their high risk, making them some of the most volatile in the market. Their prices can swing dramatically, driven by the results of FDA clinical trials and the real-world performance of their treatments. In 2020, the biotech sector surged to prominence with the rollout of COVID-19 vaccines. By late 2023 and early 2024, investor interest revived as Big Pharma began spending on acquisitions. However, the momentum slowed, and biotech stocks remained stagnant for months. In the second quarter, biopharma deal activity sharply declined, with only a few M&A deals and IPOs breaking the otherwise quiet period. This slowdown came after a lively first quarter, where pharma finally started deploying its massive cash reserves for acquisitions.

NASDAQ.NTLA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
... Over A Quarter Of Its Workforce - ARK Genomic Revolution ETF (BATS:ARKG),...

Cathie Wood-led Ark Invest made significant trades in five major companies on Friday: Recursion P...

Benzinga 11 Jan 2025

Intellia Therapeutics stock falls following strategic reorganization By...

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) fell 2.4% in pre-open trading Friday as the...

Investing.com 10 Jan 2025

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

On Thursday, Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025,...

Benzinga · via Yahoo Finance 10 Jan 2025

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the...

Zacks · via Yahoo Finance 10 Jan 2025

Intellia Therapeutics executive sells $109,205 in stock By Investing.com

CAMBRIDGE, MA—Laura Sepp-Lorenzino, Executive Vice President and Chief Scientific Officer of...

Investing.com 7 Jan 2025

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are goi...

Insider Monkey · via Yahoo Finance 30 Dec 2024

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article,...

Insider Monkey · via Yahoo Finance 29 Dec 2024

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to...

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this...

Insider Monkey · via Yahoo Finance 11 Dec 2024

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial...

Intellia Therapeutics Inc (NTLA) showcases strong financials and significant progress in its...

GuruFocus.com · via Yahoo Finance 8 Nov 2024

Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In ...

Insider Monkey · via Yahoo Finance 16 Oct 2024